Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2030-05-12
Target enrollment:
Participant gender:
Summary
This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent). Triapine inhibits an enzyme responsible for producing molecules required for the production of deoxyribonucleic acid (DNA), which may inhibit tumor cell growth. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Giving triapine in combination with temozolomide may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma.
Phase:
PHASE1
Details
Lead Sponsor:
Northwestern University
Collaborators:
BrainUp Inc National Cancer Institute (NCI)
Treatments:
3-aminopyridine-2-carboxaldehyde thiosemicarbazone Magnetic Resonance Spectroscopy Specimen Handling Temozolomide